Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
0.2736
+0.0036 (1.33%)
At close: Apr 1, 2025, 4:00 PM
0.2856
+0.0120 (4.39%)
After-hours: Apr 1, 2025, 4:34 PM EDT
Company Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States.
Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
The company is headquartered in Coral Gables, Florida.
Relmada Therapeutics, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Sergio Traversa |
Contact Details
Address: 2222 Ponce de Leon Boulevard, Floor 3 Coral Gables, Florida 33134 United States | |
| Phone | 786 629 1376 |
| Website | relmada.com |
Stock Details
| Ticker Symbol | RLMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001553643 |
| CUSIP Number | 75955J402 |
| ISIN Number | US75955J4022 |
| Employer ID | 45-5401931 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sergio Traversa M.B.A., Pharm.D. | Chief Executive Officer and Director |
| Maged S. Shenouda M.B.A., R.Ph. | Chief Financial Officer |
| Paul E. Kelly M.B.A. | Chief Operating Officer and Director |
| Charles S. Ence CPA, M.B.A. | Chief Accounting and Compliance Officer |
| Gina DiGuglielmo | Vice President and Head of Clinical Operations |
| John Hixon | Head of Commercial |
| Dr. Andrew Cutler | Senior Clinical Development Advisor |
| Dr. Richard M. Mangano Ph.D. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Feb 6, 2025 | 8-K | Current Report |
| Jan 27, 2025 | 8-K | Current Report |
| Jan 6, 2025 | 8-K | Current Report |
| Dec 9, 2024 | 8-K | Current Report |
| Dec 4, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |